
X-Linked Adrenoleukodystrophy Market
Description
X-linked Adrenoleukodystrophy Market Report and Forecast 2024-2032
The x-linked adrenoleukodystrophy market was valued at USD 239.3 million driven by the rising prevalence of neurological disorders associated with the condition, alongside increasing demand for gene therapy and stem cell transplants. It is projected to grow at a CAGR of 1.2% during the forecast period of 2024-2032 and is likely to achieve a value of USD 265.7 million by 2032.
X-linked Adrenoleukodystrophy Market Analysis
X-linked adrenoleukodystrophy is a rare genetic disorder affecting the nervous system and adrenal glands, caused by mutations in the ABCD1 gene. The disease leads to the buildup of very long-chain fatty acids in the brain and adrenal cortex, causing severe neurological and physical symptoms. It typically affects males, with its presentation ranging from childhood cerebral forms to adult-onset types, including adrenomyeloneuropathy and Addison’s disease.
Market Drivers
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
X-linked Adrenoleukodystrophy Market Segmentation
Market Breakup by Type
Market Breakup by Patient Treatment
Market Breakup by Distributor
Market Breakup by Region
X-linked Adrenoleukodystrophy Market Competitive Landscape
The competitive landscape of the x-linked adrenoleukodystrophy market includes key players such as Bluebird Bio Inc., MINORYX THERAPEUTICS SL, SwanBio Therapeutics Inc., Viking Therapeutics Inc., Novartis AG, Sanofi SA, Orpheris Inc., and Merck KGaA. These companies are actively engaged in research and development, focusing on novel therapies like gene therapy and stem cell transplants. Collaborations with academic institutions and governments are common, aimed at accelerating treatment advancements and improving patient outcomes.
Key Questions Answered in the Report
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the x-linked adrenoleukodystrophy market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the x-linked adrenoleukodystrophy market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the x-linked adrenoleukodystrophy industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The x-linked adrenoleukodystrophy market was valued at USD 239.3 million driven by the rising prevalence of neurological disorders associated with the condition, alongside increasing demand for gene therapy and stem cell transplants. It is projected to grow at a CAGR of 1.2% during the forecast period of 2024-2032 and is likely to achieve a value of USD 265.7 million by 2032.
X-linked Adrenoleukodystrophy Market Analysis
X-linked adrenoleukodystrophy is a rare genetic disorder affecting the nervous system and adrenal glands, caused by mutations in the ABCD1 gene. The disease leads to the buildup of very long-chain fatty acids in the brain and adrenal cortex, causing severe neurological and physical symptoms. It typically affects males, with its presentation ranging from childhood cerebral forms to adult-onset types, including adrenomyeloneuropathy and Addison’s disease.
Market Drivers
- Advancements in Gene Therapy: Ongoing research and development in gene therapy for x-linked adrenoleukodystrophy are driving the market, offering long-term solutions by addressing the genetic root cause of the disease. Clinical trials and successful outcomes in gene therapies are increasing patient demand.
- Newborn Screening Expansion: Growing implementation of newborn screening programs for early detection of x-linked adrenoleukodystrophy is accelerating market growth. Early diagnosis leads to faster treatment intervention, improving patient outcomes and survival rates.
- Growing Awareness and Research: Increased awareness of x-linked adrenoleukodystrophy due to patient advocacy groups, along with rising investment in rare disease research, is driving the market. Governments and private organisations are funding new treatments and diagnostic solutions.
- Stem Cell Research: The expansion of stem cell research is improving treatment prospects for x-linked adrenoleukodystrophy . Stem cell transplants are being increasingly explored as potential curative treatments, contributing to the growth of the market.
- Technological Advancements: Innovations in diagnostic tools and treatment methods, such as improved imaging techniques and personalised medicine, are enhancing early detection and tailored therapies, thereby driving the demand for effective treatments.
- Limited Awareness in Developing Regions: While awareness of x-linked adrenoleukodystrophy is increasing in developed countries, a lack of knowledge and diagnostic infrastructure in developing nations limits early detection and treatment.
- Slow Regulatory Approvals: The approval process for novel therapies, particularly gene and stem cell treatments, is often lengthy and complex. This regulatory barrier slows market growth as it delays the availability of new treatments.
- Complications with Stem Cell Transplants: Stem cell transplants carry risks such as graft-versus-host disease and rejection, which can deter patients and healthcare providers from opting for these treatments.
- Lack of Access to Specialised Care: In many regions, access to specialised medical care, including advanced treatments for x-linked adrenoleukodystrophy, is limited. This challenge hinders the effective treatment and management of the disease.
- Gene Therapy Innovations: There is significant potential in the development of gene therapies specifically targeting x-linked adrenoleukodystrophy, with growing research and increasing funding aimed at finding long-term solutions to treat the disease.
- Expansion into Emerging Markets: With rising healthcare investments and improving infrastructure in countries like India and China, companies have a major opportunity to introduce advanced x-linked adrenoleukodystrophy treatments to new markets.
- Collaboration in Drug Development: Partnerships between pharmaceutical companies, research institutes, and academic institutions can accelerate the development of new therapies, increasing treatment availability.
- Increased Focus on Early Diagnosis: As newborn screening programs expand globally, opportunities arise to enhance early diagnosis, enabling faster treatment and better patient outcomes, further supporting market growth.
- Telemedicine and Remote Care: The expansion of telemedicine offers an opportunity to deliver care for x-linked adrenoleukodystrophy patients in remote or underserved areas, improving access to specialised care without geographical constraints.
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Expansion of Gene Therapy
- Growing Focus on Newborn Screening
- Collaboration in Drug Development
- Increasing Demand for Minimally Invasive Treatments
- Growing Emphasis on Personalised Medicine
- Advancements in Stem Cell Therapy
X-linked Adrenoleukodystrophy Market Segmentation
Market Breakup by Type
- Adrenomyeloneuropathy (AMN)
- Adult cerebral ALD
- Childhood cerebral ALD
- Addison’s-only ALD
Market Breakup by Patient Treatment
- Stem cell transplant
- Adrenal insufficiency treatment
- Gene therapy Physical therapy
- Corticosteroids
- Lorenzo’s oil
- Others
Market Breakup by Distributor
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
X-linked Adrenoleukodystrophy Market Competitive Landscape
The competitive landscape of the x-linked adrenoleukodystrophy market includes key players such as Bluebird Bio Inc., MINORYX THERAPEUTICS SL, SwanBio Therapeutics Inc., Viking Therapeutics Inc., Novartis AG, Sanofi SA, Orpheris Inc., and Merck KGaA. These companies are actively engaged in research and development, focusing on novel therapies like gene therapy and stem cell transplants. Collaborations with academic institutions and governments are common, aimed at accelerating treatment advancements and improving patient outcomes.
Key Questions Answered in the Report
- What are the main drivers of the x-linked adrenoleukodystrophy market?
- What challenges are hindering the growth of the x-linked adrenoleukodystrophy treatment market?
- How is gene therapy shaping the future of x-linked adrenoleukodystrophy treatment?
- What role does newborn screening play in the early diagnosis of x-linked adrenoleukodystrophy?
- Which regions dominate the x-linked adrenoleukodystrophy market?
- How are stem cell transplants influencing treatment outcomes for severe cases?
- What are the key opportunities in emerging markets like Japan and India?
- How are advancements in diagnostic tools improving early detection of x-linked adrenoleukodystrophy?
- What collaborations are shaping the landscape of x-linked adrenoleukodystrophy research and development?
- How is the competitive landscape evolving with the introduction of novel therapies?
- What impact do retail and online pharmacies have on the distribution of x-linked adrenoleukodystrophy treatments?
- How is the global healthcare investment influencing the x-linked adrenoleukodystrophy market growth?
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the x-linked adrenoleukodystrophy market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the x-linked adrenoleukodystrophy market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the x-linked adrenoleukodystrophy industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 X-linked Adrenoleukodystrophy Market Overview – 8 Major Markets
- 3.1 X-linked Adrenoleukodystrophy Market Historical Value (2018-2024)
- 3.2 X-linked Adrenoleukodystrophy Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 X-linked Adrenoleukodystrophy Market Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Type
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 X-linked Adrenoleukodystrophy Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 X-linked Adrenoleukodystrophy Market Landscape – 8 Major Markets
- 8.1 X-linked Adrenoleukodystrophy Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 X-linked Adrenoleukodystrophy Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Treatment
- 9 X-linked Adrenoleukodystrophy Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 X-linked Adrenoleukodystrophy Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 X-linked Adrenoleukodystrophy Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 X-linked Adrenoleukodystrophy Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Adrenomyeloneuropathy (AMN)
- 12.1.3 Adult cerebral ALD
- 12.1.4 Childhood cerebral ALD
- 12.1.5 Addison’s-only ALD
- 12.2 X-linked Adrenoleukodystrophy Market (2018-2034) by Patient Treatment
- 12.2.1 Market Overview
- 12.2.2 Stem cell transplant
- 12.2.3 Adrenal insufficiency treatment
- 12.2.4 Gene therapy Physical therapy
- 12.2.5 Corticosteroids
- 12.2.6 Lorenzo’s oil
- 12.2.7 Others
- 12.3 X-linked Adrenoleukodystrophy Market (2018-2034) by Distributer
- 12.3.1 Market Overview
- 12.3.2 Hospital Pharmacy
- 12.3.3 Retail Pharmacy
- 12.3.4 Online Pharmacy
- 12.3.5 Others
- 12.4 X-linked Adrenoleukodystrophy Market (2018-2034) by Country
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 United Kingdom
- 12.4.4 Germany
- 12.4.5 France
- 12.4.6 Italy
- 12.4.7 Spain
- 12.4.8 Japan
- 12.4.9 India
- 13 United States X-linked Adrenoleukodystrophy Market (2018-2034)
- 13.1 United States X-linked Adrenoleukodystrophy Market Historical Value (2018-2024)
- 13.2 United States X-linked Adrenoleukodystrophy Market Forecast Value (2025-2034)
- 13.3 United States X-linked Adrenoleukodystrophy Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Adrenomyeloneuropathy (AMN)
- 13.3.3 Adult cerebral ALD
- 13.3.4 Childhood cerebral ALD
- 13.3.5 Addison’s-only ALD
- 13.4 United States X-linked Adrenoleukodystrophy Market (2018-2034) by Patient Treatment
- 13.4.1 Market Overview
- 13.4.2 Stem cell transplant
- 13.4.3 Adrenal insufficiency treatment
- 13.4.4 Gene therapy Physical therapy
- 13.4.5 Corticosteroids
- 13.4.6 Lorenzo’s oil
- 13.4.7 Others
- 13.5 United States X-linked Adrenoleukodystrophy Market (2018-2034) by Distributer
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacy
- 13.5.3 Retail Pharmacy
- 13.5.4 Online Pharmacy
- 13.5.5 Others
- 14 United Kingdom X-linked Adrenoleukodystrophy Market (2018-2034)
- 14.1 United Kingdom X-linked Adrenoleukodystrophy Market Historical Value (2018-2024)
- 14.2 United Kingdom X-linked Adrenoleukodystrophy Market Forecast Value (2025-2034)
- 14.3 United Kingdom X-linked Adrenoleukodystrophy Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Adrenomyeloneuropathy (AMN)
- 14.3.3 Adult cerebral ALD
- 14.3.4 Childhood cerebral ALD
- 14.3.5 Addison’s-only ALD
- 14.4 United Kingdom X-linked Adrenoleukodystrophy Market (2018-2034) by Patient Treatment
- 14.4.1 Market Overview
- 14.4.2 Stem cell transplant
- 14.4.3 Adrenal insufficiency treatment
- 14.4.4 Gene therapy Physical therapy
- 14.4.5 Corticosteroids
- 14.4.6 Lorenzo’s oil
- 14.4.7 Others
- 14.5 United Kingdom X-linked Adrenoleukodystrophy Market (2018-2034) by Distributer
- 14.5.1 Market Overview
- 14.5.2 Hospital Pharmacy
- 14.5.3 Retail Pharmacy
- 14.5.4 Online Pharmacy
- 14.5.5 Others
- 15 France X-linked Adrenoleukodystrophy Market (2018-2034)
- 15.1 France X-linked Adrenoleukodystrophy Market Historical Value (2018-2024)
- 15.2 France X-linked Adrenoleukodystrophy Market Forecast Value (2025-2034)
- 15.3 France X-linked Adrenoleukodystrophy Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Adrenomyeloneuropathy (AMN)
- 15.3.3 Adult cerebral ALD
- 15.3.4 Childhood cerebral ALD
- 15.3.5 Addison’s-only ALD
- 15.4 France X-linked Adrenoleukodystrophy Market (2018-2034) by Patient Treatment
- 15.4.1 Market Overview
- 15.4.2 Stem cell transplant
- 15.4.3 Adrenal insufficiency treatment
- 15.4.4 Gene therapy Physical therapy
- 15.4.5 Corticosteroids
- 15.4.6 Lorenzo’s oil
- 15.4.7 Others
- 15.5 France X-linked Adrenoleukodystrophy Market (2018-2034) by Distributer
- 15.5.1 Market Overview
- 15.5.2 Hospital Pharmacy
- 15.5.3 Retail Pharmacy
- 15.5.4 Online Pharmacy
- 15.5.5 Others
- 16 Italy X-linked Adrenoleukodystrophy Market (2018-2034)
- 16.1 Italy X-linked Adrenoleukodystrophy Market Historical Value (2018-2024)
- 16.2 Italy X-linked Adrenoleukodystrophy Market Forecast Value (2025-2034)
- 16.3 Italy X-linked Adrenoleukodystrophy Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Adrenomyeloneuropathy (AMN)
- 16.3.3 Adult cerebral ALD
- 16.3.4 Childhood cerebral ALD
- 16.3.5 Addison’s-only ALD
- 16.4 Italy X-linked Adrenoleukodystrophy Market (2018-2034) by Patient Treatment
- 16.4.1 Market Overview
- 16.4.2 Stem cell transplant
- 16.4.3 Adrenal insufficiency treatment
- 16.4.4 Gene therapy Physical therapy
- 16.4.5 Corticosteroids
- 16.4.6 Lorenzo’s oil
- 16.4.7 Others
- 16.5 Italy X-linked Adrenoleukodystrophy Market (2018-2034) by Distributer
- 16.5.1 Market Overview
- 16.5.2 Hospital Pharmacy
- 16.5.3 Retail Pharmacy
- 16.5.4 Online Pharmacy
- 16.5.5 Others
- 17 Spain X-linked Adrenoleukodystrophy Market (2018-2034)
- 17.1 Spain X-linked Adrenoleukodystrophy Market Historical Value (2018-2024)
- 17.2 Spain X-linked Adrenoleukodystrophy Market Forecast Value (2025-2034)
- 17.3 Spain X-linked Adrenoleukodystrophy Market (2018-2034) by Type
- 17.3.1 Market Overview
- 17.3.2 Adrenomyeloneuropathy (AMN)
- 17.3.3 Adult cerebral ALD
- 17.3.4 Childhood cerebral ALD
- 17.3.5 Addison’s-only ALD
- 17.4 Spain X-linked Adrenoleukodystrophy Market (2018-2034) by Patient Treatment
- 17.4.1 Market Overview
- 17.4.2 Stem cell transplant
- 17.4.3 Adrenal insufficiency treatment
- 17.4.4 Gene therapy Physical therapy
- 17.4.5 Corticosteroids
- 17.4.6 Lorenzo’s oil
- 17.4.7 Others
- 17.5 Spain X-linked Adrenoleukodystrophy Market (2018-2034) by Distributer
- 17.5.1 Market Overview
- 17.5.2 Hospital Pharmacy
- 17.5.3 Retail Pharmacy
- 17.5.4 Online Pharmacy
- 17.5.5 Others
- 18 Japan X-linked Adrenoleukodystrophy Market
- 18.1 Japan X-linked Adrenoleukodystrophy Market Historical Value (2018-2024)
- 18.2 Japan X-linked Adrenoleukodystrophy Market Forecast Value (2025-2034)
- 18.3 Japan X-linked Adrenoleukodystrophy Market (2018-2034) by Type
- 18.3.1 Market Overview
- 18.3.2 Adrenomyeloneuropathy (AMN)
- 18.3.3 Adult cerebral ALD
- 18.3.4 Childhood cerebral ALD
- 18.3.5 Addison’s-only ALD
- 18.4 Japan X-linked Adrenoleukodystrophy Market (2018-2034) by Patient Treatment
- 18.4.1 Market Overview
- 18.4.2 Stem cell transplant
- 18.4.3 Adrenal insufficiency treatment
- 18.4.4 Gene therapy Physical therapy
- 18.4.5 Corticosteroids
- 18.4.6 Lorenzo’s oil
- 18.4.7 Others
- 18.5 Japan X-linked Adrenoleukodystrophy Market (2018-2034) by Distributer
- 18.5.1 Market Overview
- 18.5.2 Hospital Pharmacy
- 18.5.3 Retail Pharmacy
- 18.5.4 Online Pharmacy
- 18.5.5 Others
- 19 India X-linked Adrenoleukodystrophy Market
- 19.1 India X-linked Adrenoleukodystrophy Market (2018-2034) Historical Value (2018-2024)
- 19.2 India X-linked Adrenoleukodystrophy Market (2018-2034) Forecast Value (2025-2034)
- 19.3 India X-linked Adrenoleukodystrophy Market (2018-2034) by Type
- 19.3.1 Market Overview
- 19.3.2 Adrenomyeloneuropathy (AMN)
- 19.3.3 Adult cerebral ALD
- 19.3.4 Childhood cerebral ALD
- 19.3.5 Addison’s-only ALD
- 19.4 India X-linked Adrenoleukodystrophy Market (2018-2034) by Patient Treatment
- 19.4.1 Market Overview
- 19.4.2 Stem cell transplant
- 19.4.3 Adrenal insufficiency treatment
- 19.4.4 Gene therapy Physical therapy
- 19.4.5 Corticosteroids
- 19.4.6 Lorenzo’s oil
- 19.4.7 Others
- 19.5 India X-linked Adrenoleukodystrophy Market (2018-2034) by Distributer
- 19.5.1 Market Overview
- 19.5.2 Hospital Pharmacy
- 19.5.3 Retail Pharmacy
- 19.5.4 Online Pharmacy
- 19.5.5 Others
- 20 Regulatory Framework
- 20.1 Regulatory Overview
- 20.2 US FDA
- 20.3 EU EMA
- 20.4 Japan PMDA
- 20.5 India CDSCO
- 20.6 Others
- 21 Patent Analysis
- 21.1 Analysis by Treatment of Patent
- 21.2 Analysis by Publication Year
- 21.3 Analysis by Issuing Authority
- 21.4 Analysis by Patent Age
- 21.5 Analysis by CPC Analysis
- 21.6 Analysis by Patent Valuation
- 21.7 Analysis by Key Players
- 22 Clinical Trials and Pipeline Analysis
- 22.1 Analysis by Trial Registration Year
- 22.2 Analysis by Trial Status
- 22.3 Analysis by Trial Phase
- 22.4 Analysis by Therapeutic Area
- 22.5 Analysis by Geography
- 22.6 Treatment Pipeline Assessment
- 23 Grants Analysis
- 23.1 Analysis by Year
- 23.2 Analysis by Amount Awarded
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Grant Application
- 23.5 Analysis by Funding Institute
- 23.6 Analysis by NIH Departments
- 23.7 Analysis by Recipient Organization
- 24 Funding and Investment Analysis
- 24.1 Analysis by Funding Instances
- 24.2 Analysis by Treatment of Funding
- 24.3 Analysis by Funding Amount
- 24.4 Analysis by Leading Players
- 24.5 Analysis by Leading Investors
- 24.6 Analysis by Geography
- 25 Strategic Initiatives
- 25.1 Analysis by Partnership Instances
- 25.2 Analysis by Treatment of Partnership
- 25.3 Analysis by Leading Players
- 25.4 Analysis by Geography
- 26 Supplier Landscape
- 26.1 Market Share by Top 5 Companies
- 26.2 Bluebird Bio Inc.
- 26.2.1 Financial Analysis
- 26.2.2 Product Portfolio
- 26.2.3 Demographic Reach and Achievements
- 26.2.4 Companies News and Developments
- 26.2.5 Certifications
- 26.3 MINORYX THERAPEUTICS SL
- 26.3.1 Financial Analysis
- 26.3.2 Product Portfolio
- 26.3.3 Demographic Reach and Achievements
- 26.3.4 Companies News and Developments
- 26.3.5 Certifications
- 26.4 SwanBio Therapeutics Inc.
- 26.4.1 Financial Analysis
- 26.4.2 Product Portfolio
- 26.4.3 Demographic Reach and Achievements
- 26.4.4 Companies News and Developments
- 26.4.5 Certifications
- 26.5 Viking Therapeutics Inc.
- 26.5.1 Financial Analysis
- 26.5.2 Product Portfolio
- 26.5.3 Demographic Reach and Achievements
- 26.5.4 Companies News and Developments
- 26.5.5 Certifications
- 26.6 Novartis AG
- 26.6.1 Financial Analysis
- 26.6.2 Product Portfolio
- 26.6.3 Demographic Reach and Achievements
- 26.6.4 Companies News and Developments
- 26.6.5 Certifications
- 26.7 Sanofi SA
- 26.7.1 Financial Analysis
- 26.7.2 Product Portfolio
- 26.7.3 Demographic Reach and Achievements
- 26.7.4 Companies News and Developments
- 26.7.5 Certifications
- 26.8 Merck KGaA
- 26.8.1 Financial Analysis
- 26.8.2 Product Portfolio
- 26.8.3 Demographic Reach and Achievements
- 26.8.4 Companies News and Developments
- 26.8.5 Certifications
- 26.9 Orpheris Inc.
- 26.9.1 Financial Analysis
- 26.9.2 Product Portfolio
- 26.9.3 Demographic Reach and Achievements
- 26.9.4 Companies News and Developments
- 26.9.5 Certifications
- 27 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.